MedTrace Logo

PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study

NCT06608459 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-10-17

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if it is feasible to use PEX010 for the treatment of opioid use disorder in adults. The study will also assess the safety of PEX010. The main questions it aims to answer are:

Can we successfully recruit participants, provide the drug and retain participants for the duration of the study?

What medical problems do participants experience when taking PEX010?

Participants will:

Take PEX010 twice during the study Engage in cognitive behavioural therapy Visit the clinic once or twice per week for study intervention and followup visits

Conditions

Interventions

DRUG

PEX010-Assisted Therapy

The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • Filament Health Corp.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-12-31
Completion
2027-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608459 on ClinicalTrials.gov